Literature DB >> 29244074

The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.

Mattia Arrigo1,2, Nicolas Vodovar1, Hélène Nougué1,3, Malha Sadoune1, Chris J Pemberton4, Pamela Ballan5, Pierre-Olivier Ludes5, Nicolas Gendron6,7,8, Alain Carpentier6,9, Bernard Cholley6,10, Philippe Bizouarn11, Alain Cohen-Solal1,12,13, Jagmeet P Singh14, Jackie Szymonifka15, Christian Latremouille6,9, Jane-Lise Samuel1, Jean-Marie Launay1,16, Julien Pottecher5,17, A Mark Richards4,18, Quynh A Truong15, David M Smadja6,7,8, Alexandre Mebazaa1,3,12.   

Abstract

Aims: Heart failure (HF) is accompanied by major neuroendocrine changes including the activation of the natriuretic peptide (NP) pathway. Using the unique model of patients undergoing implantation of the CARMAT total artificial heart and investigating regional differences in soluble neprilysin (sNEP) in patients with reduced or preserved systolic function, we studied the regulation of the NP pathway in HF. Methods and results: Venous blood samples from two patients undergoing replacement of the failing ventricles with a total artificial heart were collected before implantation and weekly thereafter until post-operative week 6. The ventricular removal was associated with an immediate drop in circulating NPs, a nearly total disappearance of circulating glycosylated proBNP and furin activity and a marked decrease in sNEP. From post-operative week 1 onwards, NP concentrations remained overall unchanged. In contrast, partial recoveries in glycosylated proBNP, furin activity, and sNEP were observed. Furthermore, while in patients with preserved systolic function (n = 6), sNEP concentrations in the coronary sinus and systemic vessels were similar (all P > 0.05), in patients with reduced left-ventricular systolic function, sNEP concentration, and activity were ∼three-fold higher in coronary sinus compared to systemic vessels (n = 21, all P < 0.0001), while the trans-pulmonary gradient was neutral (n = 5, P = 1.0).
Conclusion: The heart plays a pivotal role as a regulator of the endocrine response in systolic dysfunction, not only by directly releasing NPs but also by contributing to circulating sNEP, which in turn determines the bioavailability of other numerous vasoactive peptides.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29244074      PMCID: PMC6927890          DOI: 10.1093/eurheartj/ehx679

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  15 in total

1.  Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure.

Authors:  Nicolas Vodovar; Marie-France Séronde; Said Laribi; Etienne Gayat; Johan Lassus; Riadh Boukef; Semir Nouira; Philippe Manivet; Jane-Lise Samuel; Damien Logeart; Shiro Ishihara; Alain Cohen Solal; James L Januzzi; A Mark Richards; Jean-Marie Launay; Alexandre Mebazaa
Journal:  Eur Heart J       Date:  2014-08-24       Impact factor: 29.983

Review 2.  Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Authors:  Paul M McKie; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 3.  A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.

Authors:  Antoni Bayes-Genis; Jaume Barallat; A Mark Richards
Journal:  J Am Coll Cardiol       Date:  2016-08-09       Impact factor: 24.094

4.  Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study.

Authors:  Mattia Arrigo; Quynh A Truong; Duygu Onat; Jackie Szymonifka; Etienne Gayat; Heli Tolppanen; Malha Sadoune; Ryan T Demmer; Ka Y Wong; Jean Marie Launay; Jane-Lise Samuel; Alain Cohen-Solal; James L Januzzi; Jagmeet P Singh; Paolo C Colombo; Alexandre Mebazaa
Journal:  Clin Chem       Date:  2016-10-25       Impact factor: 8.327

5.  Post-transcriptional modification of pro-BNP in heart failure: is glycosylation and circulating furin key for cardiovascular homeostasis?

Authors:  Tomoko Ichiki; John C Burnett
Journal:  Eur Heart J       Date:  2014-09-21       Impact factor: 29.983

6.  Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes.

Authors:  Jason M Tonne; Jarryd M Campbell; Alessandro Cataliotti; Seiga Ohmine; Tayaramma Thatava; Toshie Sakuma; Fima Macheret; Brenda K Huntley; John C Burnett; Yasuhiro Ikeda
Journal:  Clin Chem       Date:  2011-04-11       Impact factor: 8.327

7.  Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.

Authors:  Nicolas Vodovar; Marie-France Séronde; Said Laribi; Etienne Gayat; Johan Lassus; James L Januzzi; Riadh Boukef; Semir Nouira; Philippe Manivet; Jane-Lise Samuel; Damien Logeart; Alain Cohen-Solal; A Mark Richards; Jean-Marie Launay; Alexandre Mebazaa
Journal:  JACC Heart Fail       Date:  2015-08       Impact factor: 12.035

8.  Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.

Authors:  H Yasue; M Yoshimura; H Sumida; K Kikuta; K Kugiyama; M Jougasaki; H Ogawa; K Okumura; M Mukoyama; K Nakao
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

9.  Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.

Authors:  Quynh A Truong; James L Januzzi; Jackie Szymonifka; Wai-ee Thai; Bryan Wai; Zachary Lavender; Umesh Sharma; Ryan M Sandoval; Zachary S Grunau; Sandeep Basnet; Adefolakemi Babatunde; Olujimi A Ajijola; James K Min; Jagmeet P Singh
Journal:  Heart Rhythm       Date:  2014-07-08       Impact factor: 6.343

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

View more
  8 in total

Review 1.  Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease.

Authors:  Mattia Arrigo; Pietro E Cippà; Alexandre Mebazaa
Journal:  Curr Heart Fail Rep       Date:  2018-10

Review 2.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

3.  The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.

Authors:  Noemi Pavo; Henrike Arfsten; Anna Cho; Georg Goliasch; Philipp E Bartko; Raphael Wurm; Claudia Freitag; Heinz Gisslinger; Gabriela Kornek; Guido Strunk; Markus Raderer; Christoph Zielinski; Martin Hülsmann
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

Review 4.  Neprilysin as a Biomarker: Challenges and Opportunities.

Authors:  Noemi Pavo; Suriya Prausmüller; Philipp E Bartko; Georg Goliasch; Martin Hülsmann
Journal:  Card Fail Rev       Date:  2020-08-14

Review 5.  Neprilysin expression and functions in development, ageing and disease.

Authors:  N N Nalivaeva; I A Zhuravin; A J Turner
Journal:  Mech Ageing Dev       Date:  2020-09-26       Impact factor: 5.432

6.  Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

Authors:  Egle Corrado; Giuseppe Dattilo; Giuseppe Coppola; Claudia Morabito; Enrico Bonni; Luca Zappia; Giuseppina Novo; Cesare de Gregorio
Journal:  Eur J Clin Pharmacol       Date:  2021-09-23       Impact factor: 2.953

Review 7.  Molecular mechanisms of sacubitril/valsartan in cardiac remodeling.

Authors:  Nor Hidayah Mustafa; Juriyati Jalil; Satirah Zainalabidin; Mohammed S M Saleh; Ahmad Yusof Asmadi; Yusof Kamisah
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

8.  Soluble neprilysin and survival in critically ill patients.

Authors:  Max Lenz; Konstantin A Krychtiuk; Mira Brekalo; Dominik F Draxler; Noemi Pavo; Christian Hengstenberg; Kurt Huber; Martin Hülsmann; Gottfried Heinz; Johann Wojta; Walter S Speidl
Journal:  ESC Heart Fail       Date:  2022-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.